EVALUATING
NEUROLOGY
Big pharma are dishing out billions to buy or license them: in 2023, Pfizer paid $43 billion for Seagen, AbbVie stumped up over $10 billion for ADC pioneer ImmunoGen, and Merck forked out $4 billion up-front – and potentially up to $22 billion –...
Neurology’s Return
EVALUATING Key Players
EVALUATING: Neurology